A retrospective study of pharmacological non-compliance in patients of schizophrenia with respect to quality of life

Schizophrenia is a mental disorder that disruptsthought processes, perceptions, emotional responsiveness, and socialinteractions. Although the course of schizophrenia differs from person toperson, it is usually chronic and can be severe and disabling, resulting insignificant impairments in quality of life. As treatment As approaches evolved, more emphasis was placed on re-integrating patients intotheir psychosocial environments rather than simply monitoring psychoticsymptoms. With the increasing availability of a wide range of drugs to treatmental illnesses, psychotropic medications are now an essential component inthe treatment of patients with severe mental disorders. In For patients with schizophrenia, quality of life is an important aspect ofrecovery. Quality of life (QoL) is a term that refers to the wellbeing of apopulation or an individual in terms of both positive and negative aspects oftheir existence at a particular time. Personal health (physical,mental and spiritual), relationships, education status, work environment,social status, wealth, a sense of security and safety, freedom, and autonomy indecision-making, social-belonging, and their physical surroundings are examplesof common aspects of QoL.According to Boyer et al., one of the most important variables indetermining the recurrence of schizophrenia is QoL. The better the patient’s quality of life, the less likely they are to relapse within two years.Thedevelopment of second-generation antipsychotics raised expectations that thesemedications would improve quality of life more than traditional antipsychotics. Nearly one-third of people who suffer major psychiatric disorders globally endup with a long-term disability and dependency. However, very fewIndian studies have compared the change in quality-of-life following treatmentwith typical and atypical antipsychotics.